WO2000007576A2 - INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE - Google Patents

INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE Download PDF

Info

Publication number
WO2000007576A2
WO2000007576A2 PCT/CA1999/000724 CA9900724W WO0007576A2 WO 2000007576 A2 WO2000007576 A2 WO 2000007576A2 CA 9900724 W CA9900724 W CA 9900724W WO 0007576 A2 WO0007576 A2 WO 0007576A2
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
effective amount
therapeutically effective
administering
type
Prior art date
Application number
PCT/CA1999/000724
Other languages
English (en)
French (fr)
Other versions
WO2000007576A3 (en
Inventor
Fernand Labrie
Yves Merand
Sylvain Gauthier
Louis Provencher
Van Luu-The
Original Assignee
Endorecherche, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche, Inc. filed Critical Endorecherche, Inc.
Priority to CA002339368A priority Critical patent/CA2339368A1/en
Priority to AU51449/99A priority patent/AU5144999A/en
Priority to JP2000563261A priority patent/JP2002522380A/ja
Priority to EP99936218A priority patent/EP1102582A2/en
Publication of WO2000007576A2 publication Critical patent/WO2000007576A2/en
Publication of WO2000007576A3 publication Critical patent/WO2000007576A3/en
Priority to NO20010651A priority patent/NO20010651L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
PCT/CA1999/000724 1998-08-07 1999-08-06 INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE WO2000007576A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002339368A CA2339368A1 (en) 1998-08-07 1999-08-06 Inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase
AU51449/99A AU5144999A (en) 1998-08-07 1999-08-06 Inhibition of type 3 3alpha-hydroxysteroid dehydrogenase
JP2000563261A JP2002522380A (ja) 1998-08-07 1999-08-06 タイプ３３α−ヒドロキシステロイドデヒドロゲナーゼの阻害
EP99936218A EP1102582A2 (en) 1998-08-07 1999-08-06 Inhibitors of type 3 3alpha-hydroxysteroid dehydrogenase
NO20010651A NO20010651L (no) 1998-08-07 2001-02-07 Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9562398P 1998-08-07 1998-08-07
US60/095,623 1998-08-07

Publications (2)

Publication Number Publication Date
WO2000007576A2 true WO2000007576A2 (en) 2000-02-17
WO2000007576A3 WO2000007576A3 (en) 2000-03-30

Family

ID=22252842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000724 WO2000007576A2 (en) 1998-08-07 1999-08-06 INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE

Country Status (9)

Country Link
EP (1) EP1102582A2 (es)
JP (1) JP2002522380A (es)
CN (1) CN1322130A (es)
AR (1) AR021757A1 (es)
AU (1) AU5144999A (es)
CA (1) CA2339368A1 (es)
ID (1) ID28791A (es)
NO (1) NO20010651L (es)
WO (1) WO2000007576A2 (es)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042319A2 (en) * 2000-11-27 2002-05-30 Entremed, Inc. 2-substituted estrogens as antiangiogenic agents
WO2003015820A1 (fr) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
EP1321146A2 (en) * 1998-03-11 2003-06-25 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
US6710037B2 (en) * 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
US6723858B2 (en) 1993-08-06 2004-04-20 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
EP1460969A2 (en) * 2001-11-29 2004-09-29 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US6891953B1 (en) 2000-06-27 2005-05-10 Microsoft Corporation Method and system for binding enhanced software features to a persona
WO2006003013A2 (de) * 2004-07-02 2006-01-12 Bayer Schering Pharma Aktiengesellschaft NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US7109187B2 (en) 1993-08-06 2006-09-19 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US7419972B2 (en) 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US8158612B2 (en) 2004-03-12 2012-04-17 Entremed, Inc. Methods of treating disease states using antiangiogenic agents
US8399440B2 (en) 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2014009274A1 (de) * 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft 3-substituierte estra-1,3,5 (10),16-tetraen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2014128108A1 (de) * 2013-02-21 2014-08-28 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraen-3-carboxamide zur inhibierung von 17.beta.-hydroxysteroid dehdrogenase (akr1 c3)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284345B2 (en) * 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
AU2008292420A1 (en) * 2007-08-31 2009-03-05 Astellas Pharma Inc. Piperidine derivative
CN101698834B (zh) * 2009-09-08 2012-05-23 北京利德曼生化股份有限公司 3α-羟基类固醇脱氢酶及其核苷酸序列、重组载体、重组宿主细胞和试剂盒
CN104873520A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途
CN104873525A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂及其药用组合物和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
US4340602A (en) * 1978-10-18 1982-07-20 Wayne State University Compositions inhibiting estrogen sulfotransferase activity
EP0117117A1 (en) * 1983-02-22 1984-08-29 Joachim Georg Liehr Improvements in or relating to the treatment of estrogen deficiency conditions
US4568673A (en) * 1984-03-20 1986-02-04 Wayne State University Compositions inhibiting murine MXT ductal carcinoma
WO1995004535A1 (en) * 1993-08-06 1995-02-16 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
WO1999046279A2 (en) * 1998-03-11 1999-09-16 Endorecherche, Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
US4340602A (en) * 1978-10-18 1982-07-20 Wayne State University Compositions inhibiting estrogen sulfotransferase activity
EP0117117A1 (en) * 1983-02-22 1984-08-29 Joachim Georg Liehr Improvements in or relating to the treatment of estrogen deficiency conditions
US4568673A (en) * 1984-03-20 1986-02-04 Wayne State University Compositions inhibiting murine MXT ductal carcinoma
WO1995004535A1 (en) * 1993-08-06 1995-02-16 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
WO1999046279A2 (en) * 1998-03-11 1999-09-16 Endorecherche, Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUFORT, ISABELLE ET AL: "Molecular cloning of human type 3 3.alpha.-hydroxysteroid dehydrogenase that differs from 20.alpha.-hydroxysteroid dehydrogenase by seven amino acids" BIOCHEM. BIOPHYS. RES. COMMUN. (1996), 228(2), 474-479 , XP000867346 *
LUU-THE V ET AL: "CHARACTERISTICS OF HUMAN TYPES 1, 2 AND 3 17BETA-HYDROXYSTEROID DEHYDROGENASE ACTIVITIES: OXIDATION/REDUCTION AND INHIBITION" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY,GB,ELSEVIER SCIENCE LTD., OXFORD, vol. 55, no. 5/06, page 581-587 XP000196678 ISSN: 0960-0760 *
PAGE, PHILIP C. BULMAN ET AL: "Efficient regioselective A-ring functionalization of estrogens" TETRAHEDRON (1990), 46(6), 2059-68 , XP000867284 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723858B2 (en) 1993-08-06 2004-04-20 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US7109187B2 (en) 1993-08-06 2006-09-19 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
EP1321146A2 (en) * 1998-03-11 2003-06-25 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6891953B1 (en) 2000-06-27 2005-05-10 Microsoft Corporation Method and system for binding enhanced software features to a persona
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
WO2002042319A2 (en) * 2000-11-27 2002-05-30 Entremed, Inc. 2-substituted estrogens as antiangiogenic agents
WO2002042319A3 (en) * 2000-11-27 2003-03-13 Entremed Inc 2-substituted estrogens as antiangiogenic agents
US6710037B2 (en) * 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
WO2003015820A1 (fr) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
EP1862165A2 (en) * 2001-11-29 2007-12-05 GTX, Inc. Prevention and treatment of androgen-deprivation induced hot flashes
EP2098247A3 (en) * 2001-11-29 2010-05-26 GTX, Inc. Prevention and treatment of androgen-deprivation induced loss of BMD or bone fractures
EP1666033A1 (en) * 2001-11-29 2006-06-07 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
EP1574212A1 (en) * 2001-11-29 2005-09-14 GTX Inc. Prevention and treatment of androgen-deprivation induced hot flashes, decreased lean muscle mass, loss of libido or erectile dysfunction
EP1460969A4 (en) * 2001-11-29 2005-08-17 Gtx Inc PREVENTION AND TREATMENT OF OSTEOPOROSIS INDUCED BY THE DEPRIVATION OF ANDROGEN
EP1460969A2 (en) * 2001-11-29 2004-09-29 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
EP1862165A3 (en) * 2001-11-29 2008-06-25 GTX, Inc. Prevention and treatment of androgen-deprivation induced hot flashes
US8158612B2 (en) 2004-03-12 2012-04-17 Entremed, Inc. Methods of treating disease states using antiangiogenic agents
JP2008504338A (ja) * 2004-07-02 2008-02-14 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト １７β−ヒドロキシステロイドデヒドロゲナーゼタイプ１のインヒビターとしての新規２−置換されたエストラ−１，３，５（１０）−トリエン−１７−オン
US7419972B2 (en) 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
WO2006003013A2 (de) * 2004-07-02 2006-01-12 Bayer Schering Pharma Aktiengesellschaft NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1
WO2006003013A3 (de) * 2004-07-02 2006-06-22 Schering Ag NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1
US8399440B2 (en) 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2014009274A1 (de) * 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft 3-substituierte estra-1,3,5 (10),16-tetraen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN104428309A (zh) * 2012-07-10 2015-03-18 拜耳医药股份有限公司 3-取代的雌甾-1,3,5(10),16-四烯衍生物、其制备方法、包含其的药物制剂及其用于制备药物的用途
US9512169B2 (en) 2012-07-10 2016-12-06 Bayer Pharma Aktiengesellschaft 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
WO2014128108A1 (de) * 2013-02-21 2014-08-28 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraen-3-carboxamide zur inhibierung von 17.beta.-hydroxysteroid dehdrogenase (akr1 c3)
CN105008382A (zh) * 2013-02-21 2015-10-28 拜耳医药股份公司 用于抑制17β-羟类固醇脱氢酶(AKR1 C3)的雌甾-1,3,5(10),16-四烯-3-羧酰胺
AP3826A (en) * 2013-02-21 2016-09-30 Bayer Pharma Aktiengellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
US9714266B2 (en) 2013-02-21 2017-07-25 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)

Also Published As

Publication number Publication date
CA2339368A1 (en) 2000-02-17
JP2002522380A (ja) 2002-07-23
NO20010651D0 (no) 2001-02-07
AU5144999A (en) 2000-02-28
NO20010651L (no) 2001-04-05
AR021757A1 (es) 2002-08-07
ID28791A (id) 2001-07-05
CN1322130A (zh) 2001-11-14
EP1102582A2 (en) 2001-05-30
WO2000007576A3 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
EP1102582A2 (en) Inhibitors of type 3 3alpha-hydroxysteroid dehydrogenase
US6541463B1 (en) Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use
EP1019060B1 (en) Androgen synthesis inhibitors
US5763432A (en) Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use
JP4866740B2 (ja) へリックス１２指向ステロイド系医薬品
US6046186A (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
US9284345B2 (en) 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US11072632B2 (en) Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10
JP2001524487A (ja) アンドロゲンステロイド化合物並びにその調製法及び使用法
US5264427A (en) 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
US5486511A (en) 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
JP2014094952A (ja) 局所活性「ソフト」抗アンドロゲン剤
US10265329B2 (en) Altering steroid metabolism for treatment of steroid-dependent disease
JP3325026B2 (ja) ４−アザ−プレグナン５α−レダクターゼアイソザイム１阻害剤
JP5290189B2 (ja) ６−アルコキシアルキルエストラジオール誘導体およびその使用
MXPA01001405A (es) Inhibicion de 3-alfa-hidrohi-esteroide-deshidrogenasa tipo 3
EP1321146A2 (en) Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
AU2004200173A1 (en) Inhibitors of Type 5 and Type 3 17B-Hydroxysteroid Dehydrogenase and Methods for Their Use
JPH06510982A (ja) 抗テストステロン化合物およびその使用方法
Weintraub et al. 4-Amino-17β-(Cyclopropyloxy) androst-4-en-3-one, 4-Amino-17β-(Cyclopropylamino) androst-4-en-3-one and Related Compounds as C17, 20-Lyase and 5α-Reductase Inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99811739.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase in:

Ref document number: 2339368

Country of ref document: CA

Ref document number: 2339368

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999936218

Country of ref document: EP

Ref document number: 509741

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 141298

Country of ref document: IL

Ref document number: PA/a/2001/001405

Country of ref document: MX

Ref document number: 200101046

Country of ref document: ZA

Ref document number: 51449/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999936218

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999936218

Country of ref document: EP